Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.54 |
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | APAF1 | O14727 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CCNC | P24863 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29812245 | 1.00 | KDM1A (0.54) | KDM1ANCF1MEN1APAF1KMT2A | |
| SCHEMBL1897179 | 0.86 | ERBB2 (0.55) | NCF1KMT2AERBB2KDRBRAF | |
| SCHEMBL12386844 | 0.83 | KDR (0.48) | MEN1KMT2AERBB2KDRBRAF | |
| SCHEMBL27303568 | 0.83 | KDR (0.49) | NCF1MEN1KMT2AERBB2KDR | |
| SCHEMBL29802752 | 0.83 | KDR (0.55) | NCF1ERBB2KDRBRAFMAPK14 | |
| SCHEMBL12410465 | 0.83 | MPO (0.48) | NCF1ERBB2KDRBRAFMAPK14 | |
| SCHEMBL4364903 | 0.83 | NCF1 (0.50) | NCF1KDRBRAFMAPK14TNNI3K | |
| SCHEMBL9431770 | 0.82 | NCF1 (0.54) | NCF1ERBB2KDRBRAFMAPK14 | |
| SCHEMBL29995286 | 0.80 | KDR (0.52) | NCF1ERBB2KDRBRAFMAPK14 | |
| SCHEMBL4360333 | 0.79 | NCF1 (0.46) | NCF1MEN1KMT2AERBB2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371428-B2 | Pyridone compounds and methods of use | EXELIXIS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20240158393-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | EXELIXIS, INC. | 2024-05-16 | — | — | US | disclosed |
| EP-4294804-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | Exelixis, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
| EP-4110779-A1 | COMPOUNDS AND METHODS OF USE | Exelixis, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| US-20220315579-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | EXELIXIS, INC. | 2022-10-06 | — | — | US | disclosed |
| US-20220306640-A1 | HYDANTOIN DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-09-29 | — | — | US | disclosed |
| EP-4034532-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE IN THE MODULATION OF A PROTEIN KINASE | Exelixis, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-4025570-A1 | HYDANTOIN DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2022-07-13 | — | — | EP | disclosed |
| US-20220194902-A1 | Method of Preparing Fluorine-18 Labeled Cabozantinib and Its Analogs | EXELIXIS, INC. | 2022-06-23 | — | — | US | disclosed |
| US-9169241-B2 | Quinolinyloxyphenylsulfonamides | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2015-10-27 | — | — | US | disclosed |
| CN-102574804-B | Quinolinyloxyphenylsulfonamides | MAX PLANCK GESELLSCHAFT | 2015-01-07 | — | — | CN | disclosed |
| US-20140336191-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20140221425-A1 | Quinolyl-containing Hydroxamic Acid Compound and Preparation Method Thereof, and Pharmaceutical Composition Containing This Compound and Use Thereof | BEIJING KONRUNS PHARMACEUTICAL CO., LTD. (CN) | 2014-08-07 | — | — | US | disclosed |
| US-20120277231-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-11-01 | — | — | US | disclosed |
| EP-2262772-B1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2012-07-18 | — | — | EP | disclosed |
| EP-2462117-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-06-13 | — | — | EP | disclosed |
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-04-21 | — | — | US | disclosed |
| WO-2011045084-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2011-04-21 | — | — | WO | disclosed |
| EP-2311809-A1 | Quinolinyloxyphenylsulfonamides | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2011-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371428-B2 | Pyridone compounds and methods of use | PDXK, PLK2, MAP4K2 | KDM1A 3828/4885NCF1 1913/4885MEN1 3040/4885 |
| US-20140336191-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | TP53, AQP1, KRAS | KDM1A 3793/4885NCF1 2063/4885MEN1 741/4885 |
| US-20120277231-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | TP53, AQP1, KRAS | KDM1A 3793/4885NCF1 2063/4885MEN1 741/4885 |
| US-20140221425-A1 | Quinolyl-containing Hydroxamic Acid Compound and Preparation Method Thereof, and Pharmaceutical Composition Containing This Compound and Use Thereof | HDAC5, HDAC1, HDAC7 | KDM1A 179/4885NCF1 2038/4885MEN1 2340/4885 |
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | PRKACB, PRKACA, PRKX | KDM1A 4203/4885NCF1 1305/4885MEN1 3817/4885 |
| US-20220315579-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, PLK2, MAP4K2 | KDM1A 3828/4885NCF1 1913/4885MEN1 3040/4885 |
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | AXL, FLT3, TYRO3 | KDM1A 2996/4885NCF1 1281/4885MEN1 1219/4885 |
| US-20220306640-A1 | HYDANTOIN DERIVATIVE | DDR1, DDR2, DDRGK1 | KDM1A 207/4885NCF1 339/4885MEN1 679/4885 |
| US-20240158393-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, PLK2, MAP4K2 | KDM1A 3828/4885NCF1 1913/4885MEN1 3040/4885 |
| US-20220194902-A1 | Method of Preparing Fluorine-18 Labeled Cabozantinib and Its Analogs | FGFR1, FLT1, PDGFRA | KDM1A 453/4885NCF1 2497/4885MEN1 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.